Year Founded
2007
Ownership
Private
Therapeutic Areas
NeurologyPsychiatry
Stage
Commercial
Modalities
Small molecule

Neurelis General Information

FDA-approved VALTOCO (diazepam nasal spray) for acute treatment of seizure clusters. Over 4,000 seizures treated in long-term clinical trials with generally safe and well-tolerated results.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

diazepam
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Neurelis's pipeline data

Book a demo

Key Partnerships

Dr. Reddy's Laboratories, ARS Pharmaceuticals

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Neurelis Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Neurelis's complete valuation and funding history, request access »